Lamivudine, nevirapine, zidovudine
Sold as Triplavar, Vutalin, Comozen, Trayroca, Mivirdo, Cipla duovir and nevirapine co-pack
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 5
- Registrations
- 6
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Cipla Medpro (Pty) Ltd1 of 2 cancelled | Triplavar, Cipla duovir and nevirapine co-pack | Not stated | 420001, A400261 | S4 | None |
| Aurobindo Pharma (Pty) LtdCancelled | Vutalin | Not stated | 430564 | S4 | None |
| Bliss Pharmaceuticals (Pty) LtdCancelled | Comozen | Not stated | 440009 | S4 | None |
| Pharmacare limited û woodmead | Trayroca | Not stated | 440636 | S4 | None |
| Viatris Healthcare (Pty) Ltd | Mivirdo | Not stated | 450388 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Triplavar EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg ZIDOVUDINE 300,0 mg | Not listed | 42000142/20.2.8/0001 | Registered | S4 | None |
| Vutalin EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg ZIDOVUDINE 300,0 mg | Not listed | 43056443/20.2.8/0564 | Cancelled | S4 | None |
| Comozen EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg ZIDOVUDINE 300,0 mg | Not listed | 44000944/20.2.8/0009 | Cancelled | S4 | None |
| Trayroca EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg ZIDOVUDINE 300,0 mg | Not listed | 44063644/20.2.8/0636 | Registered | S4 | None |
| Mivirdo EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg ZIDOVUDINE 300,0 mg | Not listed | 45038845/20.2.8/0388 | Registered | S4 | None |
| Cipla duovir and nevirapine co-pack EACH TABLET CONTAINS LAMIVUDINE 150,0 mg NEVIRAPINE 200,0 mg ZIDOVUDINE 300,0 mg | Not listed | A400261A40/20.2.8/0261 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence medium.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Lamivudine, nevirapine, zidovudine
S4: Lamivudine
Consolidated Schedules 06 July 2026, line 6850
S4: Nevirapine
Consolidated Schedules 06 July 2026, line 7245
S4: Zidovudine
Consolidated Schedules 06 July 2026, line 8412
Pharmacological class: Antiviral agents. (class 20.2.8)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.